Phase-Appropriate Signal Detection In Clinical Trials: A Framework For Phase I, II And III Safety Surveillance

By Dr. Mohit Raizada, BDS, Director, Signal Management Services, IQVIA

Spotting safety signals in a clinical trial is not a scaled-down version of post-marketing drug safety monitoring. Trials work with smaller, controlled populations, defined exposure and comparator data that may be thin or robust, and those conditions change as a program moves from first-in-human dosing to pivotal studies. This paper lays out a phase-appropriate framework for signal detection.

Across every phase, four foundations hold: governance that grows with the program, documentation that keeps every decision traceable, analytics that inform rather than decide, and expert medical judgment at the center. The paper also explores how AI may speed up case review, trend analysis, and aggregate reporting while qualified professionals keep ownership of safety decisions. Read on to learn how to match your signal detection methods to your stage of development, so you avoid overreading sparse early data, catch rarer and delayed risks later, and stay audit-ready from first dose to submission.